Provider Resources to Support Patients

Expert Think Tank on Applying the Latest Data to Individualize Treatment in Prostate Cancer

In this module, Alicia K. Morgans, MD, MPH, leads a discussion with colleagues—Tanya B. Dorff, MD; Rana R. McKay, MD; Michael T. Schweizer, MD; and David VanderWeele, MD, PhD—on incorporating the latest evidence on prostate cancer therapy into clinical practice including challenging case scenarios. This activity was developed through a partnership with Clinical Care Options (CCO) and will expire on August 15, 2024.

Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care

Learn how hormonal therapy and treatment intensification strategies are changing outcomes for patients with prostate cancer by joining Matthew R. Smith, MD, PhD, Neeraj Agarwal, MD, and Tanya Dorff, MD. Produced in partnership with PeerView Institute for Medical Education, this in-person (at the ASCO GU 2023 Symposium) and virtual event featured best practices for bringing guideline-recommended and emerging strategies to the clinic and engaging patients, caregivers, and other colleagues in personalized, collaborative care.

PARP Inhibitors in Prostate Cancer and the Rationale Behind Combination Treatment

In this micro e-learning program, providers will learn about PARP inhibitors in prostate cancer from independent experts Assoc. Prof. Alicia Morgans, MD, MPH, and Dr. Pasquale Rescigno. Module 1 covers the use of PARP inhibitors as monotherapy in advanced prostate cancer, and in module 2, the experts will explore the rationale behind combination treatment with anti-androgens. After watching the videos, take the assessments to earn CME credits. This activity was developed through a partnership with COR2ED and was released in January 2023.

Case Review: Team-Based Approaches to Optimize Androgen Deprivation Therapy in Advanced Prostate Cancer

Prostate cancer experts Alicia K. Morgans, MD, MPH, Pranav Sharma, MD, and Diane G. Cope, PhD, APRN, BC, AOCNP provide learners with skills and knowledge to work more closely with members of the interprofessional team to individualize treatment for patients with advanced prostate cancer so they may optimize their use of androgen deprivation therapy, or ADT. This activity was developed through a partnership with Medscape and was released on November 22, 2022. Available until November 22, 2023.

Creating a Roadmap for Modern Prostate Cancer Care: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision Making to Personalize Patient Care

Prostate cancer experts Alicia K. Morgans, MD, MPH, and Mark T. Fleming, MD highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. This activity was planned and implemented through a partnership with Medical Learning Institute, Inc., and PVI, PeerView Institute for Medical Education. For more information and to view the webinar and practice aids, click here. Available until October 30, 2023.

Use of PARP Inhibitor Plus AR-Signaling Inhibitor Combinations for Patients with mCRPC: A medical oncologist's perspective

In this expert commentary, Rana R. McKay, MD, offers her perspective on how the latest approvals of combination therapy with a PARP inhibitor and an AR-signaling inhibitor will affect treatment choices for patients with mCRPC. Provided by Clinical Care Options, LLC., in partnership with ZERO.

Nursing Support for mCRPC patients during radiopharmaceutical treatment

In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC). Watch the video and download the accompanying slides to learn about: a) the considerations for treatment selection in clinical practice to minimize the impact on patients' lives; b) applying recent data to treatment sequencing in bone-dominant mCRPC; and c) educating and supporting patients during treatment so they know what to expect Provided by COR2ED, in partnership with ZERO.

Treatment intensification in mCSPC: The nurse perspective

In this podcast, oncology nurses Brenda Martone and Jennifer Sutton discuss how to use data to select the most appropriate treatments for patients with metastatic castration-sensitive prostate cancer. They also share the importance of being able to explain these clinical decisions to patients and reassure them that earlier intensive treatment can prolong overall survival without seriously impacting quality of life. Provided by COR2ED, in partnership with ZERO.

Podcast: Which mCSPC patients benefit from early treatment intensification?

In this podcast, you'll hear Dr. Shilpa Gupta, MD and Dr. Fabio Schutz review patient cases to explore which patients with metastatic castration-sensitive prostate cancer (mCSPC) benefit from early treatment intensification. They discuss how to apply key data from ARASENS and PEACE-1 in clinical practice, triplet therapy as the new standard of care, and the patient subgroups that benefit the most from early treatment intensification. Provided by COR2ED, in partnership with ZERO.

The Role of the Nurse in nmCRPC Patient Management

In this video, Research Nurse Coordinator Pablo Peinado discusses selecting treatments for nmCRPC in clinical practice to minimize the impact on the patient's quality of life, and how nurses can support and educate their patients, so they know what to expect during treatment. Provided by COR2ED, in partnership with ZERO.

Podcast: PARP Inhibitors Alone or In Combination with Novel Hormonal Agents in Prostate Cancer

In this podcast series, GU oncologists discuss PARP inhibitors for prostate cancer, given alone or in combination with novel hormonal agents (NHAs). Listen to episodes 1 and 2 to hear Dr. Elena Castro and Dr. Neal Shore share their views and discuss the clinical implementation of PARP inhibitor monotherapy for prostate cancer patients and PARP inhibitors and NHA combination therapy for patients with mCRPC. Neeraj Agarwal, MD, and Tanya Dorff, MD, continue the conversation in episode 3 and cover the latest data from ASCO GU 2023. Provided by COR2ED, in partnership with ZERO.

The Prostate Cancer Clinical Masterclass Series

The Prostate Cancer Clinical Masterclass Series is a free, on-demand education series for clinicians, co-chaired by Dr. Sumit Subudhi and Dr. Gert Attard. It boasts a faculty of 24 guest presenters who are leading clinicians within the global prostate cancer space. This twelve-month initiative consists of monthly episodes which are led by two guest presenters, who will each deliver a fifteen-minute presentation, followed by a group discussion with the co-chairs.

The purpose of published guidelines are to provide providers and patients with evidence-based and consensus-based best practices for diagnosing, treating, and managing prostate cancer. The American Urologic Association publishes healthcare provider guidelines for early detection, localized prostate cancer, advanced prostate cancer, and radiotherapy.

In addition, the National Comprehensive Cancer Network (NCCN) Guidelines document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes. Patient guidelines are also available through the NCCN.